Business Wire

Ascend Expands Antimicrobial Acteev™ Technology Into Finished Goods Line to Combat COVID-19 Spread

Share

A new line of face masks combining comfort with protection is available from Acteev™ by Ascend Performance Materials, a manufacturer of technology-forward textiles and engineered materials. The brand’s first product, the Acteev Protect™ Nonwoven Mask, is a reusable general purpose mask that features powerful built-in antimicrobial technology to protect the mask from odor-causing bacteria and mold fungi in a soft, breathable, comfortable fabric that is gentle on the skin.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200910005748/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Acteev Protect Nonwoven Mask is a reusable general purpose mask that features powerful built-in antimicrobial technology to protect the mask from odor-causing bacteria and mold fungi in a soft, breathable, comfortable fabric that is gentle on the skin. (Photo: Business Wire)

The mask is the first in a series of planned Acteev product introductions that will include a knit fabric mask and a sports gaiter. The company also announced it is designing an N95 respirator and a line of surgical masks and is developing more engineering plastics solutions for high-touch surfaces such as light switches and tray tables; textiles for use in scrubs and hospital gowns; and nonwoven fibers and rolled goods for use in applications such as filtration systems.

The expansion into masks is a natural extension for Ascend, which is the largest producer of nylon 6,6 resin in the world, said Lu Zhang, Ph.D., who joined Ascend earlier this year as vice president and leader of the Acteev business. “The nylon Ascend makes is durable enough to be used under the hood of a car, but when it’s spun into fibers, it can be woven or knitted into fabrics that are soft and silky,” she said. “Combined with our antimicrobial Acteev technology, our fabric makes an Acteev Protect Nonwoven Mask more breathable, more comfortable and more wearable than anything else we’ve encountered in the market.”

The Acteev Protect Nonwoven Mask is an ideal choice for anyone seeking better protection, comfort and breathability than a typical blue mask and better availability than an N95 respirator, which are reserved for health care workers, Zhang said.

“Masks only inhibit the spread if they’re worn – that’s why comfort and breathability are so important,” Zhang said. “As we send our kids back to school, return to the workplace, resume shopping and otherwise get back to normal life, we need an option that is long-lasting and wearable for hours.

“They’re great for teachers, restaurant staff, transportation workers, industrial personnel and anyone whose lifestyle takes them out of their homes and into the world,” Zhang said.

Darayus Pardivala, the president of the Americas division of Sulzer Rotating Equipment Services, purchased the masks for employees at all 32 of the company’s locations in North and South America. “They’re much easier to breathe through compared to what we had in the past, there’s an added level of protection and our employees are much more comfortable,” Pardivala said. “The pushback we had in the past about wearing masks is completely gone.”

Recent testing on the knit fabric completed at the University of Cambridge has demonstrated that Acteev technology deactivates the virus that causes COVID-19, SARS-CoV-2, with 99.9% efficacy on contact1. Ascend is working with the U.S. Environmental Protection Agency, the U.S. Food and Drug Administration and other governmental agencies to obtain the appropriate regulatory clearances to make specific claims regarding the technology’s antiviral properties.

Acteev Protect Nonwoven Masks are made with Acteev™ technology with active zinc ions in a polymer matrix to destroy microbes.

“Acteev’s active layer of defense uses safe, environmentally friendly active zinc ions embedded into the matrix of the polymer – not a chemical spray that will wash away or flake off – meaning these masks can be used again and again,” said Phil McDivitt, CEO of Ascend.

The Acteev Protect Nonwoven Masks are constructed with three layers of zinc-embedded materials.

“Our scientists and engineers invented a process for creating a revolutionary new fabric that checks all the boxes,” McDivitt said. “Acteev™ fabric is soft to the touch and moisture-wicking to keep the face cool, and it’s more breathable than other materials used in masks.”

Product availability can be found at acteev.com and on social media: @acteevbyascend on Instagram, Twitter and Facebook.

About Ascend Performance Materials

Ascend Performance Materials makes high-performance materials for everyday essentials and new technologies. Our focus is on improving quality of life and inspiring a better tomorrow through innovation. Based in Houston, Texas, and with regional offices in Shanghai, Brussels and Detroit, we are a fully integrated material solutions provider with eight global manufacturing facilities in the United States, Europe and China. Our 2,600-person global workforce makes the plastics, fabrics, fibers and chemicals used to make safer vehicles, cleaner energy, better medical devices, smarter appliances and longer-lasting apparel and consumer goods. We are committed to safety, sustainability and the success of our customers and our communities.

Find out more about Ascend at www.ascendmaterials.com.

About Acteev: acteev.com

  • Tests show >99% antiviral, antibacterial, antifungal efficacy1
  • EPA-registered zinc ions embedded in the polymer
  • Hygroscopic nylon 6,6 fabric attracts moisture, which activates the zinc ions
  • Not a topical treatment or coating
  • Not dependent on silver, copper
  • Proven efficacy in many end forms:
    • Knit and woven fabrics for consumer textiles, upholstery, uniforms, face masks
    • Nanofiber, meltblown and spunbond nonwovens for filtration
    • Fibers for carpets
    • Engineered plastics for high-touch surfaces

1DISCLAIMER: Acteev™ technology has been shown in laboratory tests to destroy SARS-CoV-2, the coronavirus that causes COVID-19, and other pathogens including H1N1, coronavirus 229E and Gram-positive and Gram-negative bacteria such as staphylococcus and E. coli. All data presented on this page comes from testing performed by independent third-party laboratories. Testing conducted on various end forms. Testing by University of Cambridge found a >3 log (99.9%) reduction in SARS-CoV-2 and H1N1 viruses upon instant contact on polyamide 66 textile fabric with Acteev technology as compared to an identical basis weight polyamide 66 textile fabric without Acteev technology. Acteev Protect does not protect users or others against disease-causing bacteria. Not all claims are permitted in all jurisdictions, including in the United States. Some device designs currently under review with the U.S. Food and Drug Administration. Ascend has more than 15 patent families pending on Acteev technology.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nicki Britton, +1 832-205-4854, nbritt@ascendmaterials.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye